Biosimilar Drug Development 2016: Confirmed Speakers

Claudio Albrecht, Former CEO and Chairman of the Board of Directors, Actavis Group, Founder and Managing Partner, Albrecht, Prock & Partners AG

Mr Sandeep Athalye, Vice President and Head CDMA, Biosimilars, Boehringer Ingelheim

Ms Caroline Boulliat, Immunology Franchise Head of Biosimilars for Europe, Middle East and Africa, Hospira

Mazen S Darwazeh, Vice Chairman President & CEO MENA & Emerging Markets, Hikma Pharmaceuticals

Mazen S Darwazeh at Biosimilar Drug Development World Europe 2016

Dr. Ruth Ellis, Senior Consultant, Biologics Consulting Group Inc

Mr Uwe Gudat, Head of Safety, Biosimilars, Merck Serono

Dr Cyrus Karkaria, President - Biotechnology, Lupin Pharma

Ms Andrea Laslop, Head of Scientific Office, Medicinal Products for Human Use - European Medicines Agency

Mr Bernd Liedert, Program Director Biosimilars, Boehringer Ingelheim Pharma Co Gmbh

Mr Bruce Lott, Vice President of State Government Relations, Mylan Inc.

Dr Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway

Dr Steinar Madsen at Biosimilar Drug Development World Europe 2016

Dr Malcolm Mitchell, Medical Fellow, Eli Lilly and Co

Dr Rustom Mody, Senior Vice President and Head R&D, Lupin Biotech Ltd

Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan

Mr Ashwin Pai, Senior Vice President Healthcare Investment Banking, Jefferies International

Federico Pollano, Director of Contract Manufacturing and Business Development, Polpharma Biologics

Dr Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines

Dr Michael Reilly at Biosimilar Drug Development World Europe 2016

Mr Karsten Roth, Head Clinical Operation, Cinfa Biotech GmbH


"Quality presentations by industry leaders. Great chance to network. Good coverage of hot issues on the agenda of all key players"

Senior VP, Europe and Asia, Actavis



Register Now